Center to Accelerate Population Research in Alzheimer's (CAPRA)

加速阿尔茨海默病人群研究中心 (CAPRA)

• 批准号: 10689677
• 负责人: Julie PW Bynum
• 金额: $ 83.53万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10689677
• 关键词: Acceleration; Address; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Archives; Area; Behavioral Risk Factor Surveillance System; Caring; Collaborations; Communities; Complex; Consult; Consumption; Country; Data; Data Sources; Dementia; Diffusion; Discipline; Disease; Disparity; Drug Prescriptions; Economics; Funding; Future; Goals; Government; Health; Health Services; Health Services Accessibility; Health system; Healthcare; Home; Individual; Infrastructure; Institution; Interdisciplinary Study; International; Investigation; Investments; Knowledge; Leadership; Link; Long-Term Care; Medicare; Methods; Michigan; National Health and Nutrition Examination Survey; Outcome; Personal Satisfaction; Persons; Pilot Projects; Policies; Policy Maker; Population; Population Research; Populations at Risk; Positioning Attribute; Prevention; Program Development; Public Health; Public Policy; Quality of Care; Ramp; Research; Research Personnel; Research Training; Resource Allocation; Resource Development; Resources; Science; Societies; Surveys; System; Time; Training; Universities; cardiovascular risk factor; cost; design; drug quality; effective therapy; end of life; falls; health care delivery; health care service organization; improved outcome; innovation; multidisciplinary; new technology; novel diagnostics; novel therapeutics; organizational structure; population based; prevent; social; tool

Project Abstract (Overall) The population with Alzheimer’s Disease and related dementias (AD/ADRD) globally is expected to nearly triple by 2050. With few effective treatments either to prevent the disease or slow its progression, we are currently limited to managing established disease and minimizing further negative outcomes, at a cost of $200 billion per year. The National Alzheimer’s Project Act (NAPA) was passed with the goal of reducing the burden of AD/ADRD, not just for persons with dementia but also for the society at large, including the social, economic, and health system effects. There are large gaps in our knowledge about how policy-makers, public health planners and healthcare organizations can best prepare for and respond to the broad population effects of AD/ADRD as we await a cure. The proposed Center to Accelerate Population Research in Alzheimer’s (CAPRA) at the University of Michigan will be focused on science that informs government and healthcare organization actions to address the negative impacts of dementia on the health and financial well-being of individuals and the population. Our focus on public policy and healthcare for persons with dementia falls into four inter-related themes: 1) healthcare delivery and policy impact on outcomes and quality of care, 2) diffusion of new technologies, 3) disparities in quality and access to care, and 4) innovative applications of population data that inform allocation of resources and program development. The CAPRA leadership team is uniquely positioned to leverage its own expertise across these themes and the depth of institutional expertise at the University of Michigan across health services, economic, and population research to accelerate and expand population-based observational AD/ADRD research. The overarching goal for CAPRA is that it will serve as a national resource to enable and expand research by current and future leaders in the study of healthcare delivery, economics, and policies to reduce the burden of AD/ADRD locally, nationally, and internationally. To do so, the Center will act as an “on-ramp” to fast-track junior and established investigators transitioning into AD/ADRD research by funding pilot studies, providing research training and tools, giving access to unique secondary data relevant to AD/ADRD, and developing networks of experts with whom to consult and collaborate. CAPRA seeks to become the leading national resource to promote and accelerate studies that aim to reduce the social, economic, and health burden of AD/ADRD on the population. The research that emanates from this new Center will have real-world implications for health systems, payers, and policymakers as they struggle with designing effective policies to improve outcomes for the growing population with or at risk for AD/ADRD.

项目摘要（总体） 全球患有阿尔茨海默氏病和相关痴呆症（AD/ADRD）的人口几乎将几乎 到2050年，三倍。几乎没有有效的治疗方法可以预防疾病或减缓其进展，我们是 目前仅限于管理已建立疾病并最大程度地减少负面结果，费用为200美元 每年十亿。 《国家阿尔茨海默氏症计划法》（NAPA）的通过，目的是减少烧伤 AD/ADRD，不仅适用于患有痴呆症的人，还适用于整个社会，包括社会， 经济和卫生系统的影响。我们关于政策制定者，公众如何的知识有很大的差距 健康规划师和医疗保健组织可以最好地为广泛的人口影响做准备并做出反应 当我们等待治疗时，广告/adrd拟议的中心加速了阿尔茨海默氏症的人口研究 密歇根大学（CAPRA）将重点放在科学上，该科学通知政府和医疗保健 组织行动解决痴呆症对痴呆症对健康和财务福祉的负面影响 个人和人口。我们专注于痴呆症患者的公共政策和医疗保健 四个相互关联的主题：1）医疗保健提供和政策对结果和护理质量的影响，2）扩散 新技术，3）质量和获得护理方面的差异； 4）人口的创新应用 为资源和计划开发分配的数据。卡普拉领导团队是独特的 定位在这些主题中利用自己的专业知识以及在 密歇根大学跨健康服务，经济和人口研究，以加速和扩展 基于人群的观察性广告/ADRD研究。 CAPRA的总体目标是它将充当 国家资源以实现和扩大当前和未来领导者研究的研究 交付，经济学和政策，以减少当地，国内和国际上的广告/adrd的燃烧。到 这样做，该中心将充当快速训练初级的“坡道”，并确定的调查员过渡到 通过资助试点研究，提供研究培训和工具的广告/ADRD研究，可访问独特 与AD/ADRD相关的二级数据，并开发了与之咨询和咨询的专家网络 合作。卡普拉（Capra）寻求成为促进和加速研究的领先国家资源 减少AD/ADRD对人口的社会，经济和健康伯恩。散发的研究 从这个新中心将对卫生系统，付款人和政策制定者产生现实影响 努力设计有效的政策，以改善有或有风险不断增长的人口的结果 广告/adrd。